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Background and purpose: Previous retrospective studies seem to indicate that decompressive 
surgery in context of cerebral venous and dural sinus thrombosis is a life-saving procedure in 
patients at high risk for transtentorial herniation. An interim analysis of the ongoing prospective 
registry for Decompressive Surgery in Cerebrovenous Thrombosis was performed in order to 
identify potential outcome predictors and assess for the feasibility of a larger registry. 
Methods: Patients were included in a multicentric prospective cohort with pre-specified eligibility 
criteria. Primary endpoint was defined as death or dependency at 6 months follow-up, and two other 
secondary endpoints were chosen to differentiate effects on short and long-term outcomes: deaths 
within 30 days after symptom onset; and late deaths or dependencies at 6 months follow-up. 
Results: Twenty-two participants were enrolled from 8 different countries. Mortality at 6 months 
was of 23.8%, whereas death or dependency rate for the same period reached 57.1%. A primary 
endpoint predictor with significant effect in the short-term outcome was new haemorrhagic 
transformation before first neurosurgical intervention (P=0.029), while overall outcome predictors 
with significant influence on the long-term were: post-operative complication with an extracranial 
infection (P=0.016); and smaller bone flap sizes during craniectomy (P=0.044). 
Conclusions: The low mortality rates with decompressive surgery continue to support the 
indications for this procedure. Defining an appropriate size for decompressive craniectomy, as well 
as strategies to minimize haemorrhagic transformation events could further improve patients’ 
outcome. 
Resumo 
Enquadramento teórico e objectivos: A cirurgia descompressiva na trombose venosa cerebral tem-
se afirmado cada vez mais como um procedimento life-saving em doentes com risco de desenvolver 
herniação transtentorial. Neste sentido fez-se uma análise intercalar do registo sobre Cirurgia 
Descompressiva no contexto desta entidade clínica, com o objectivo de identificar potenciais 
variáveis preditoras do prognóstico, bem como aferir sobre a viabilidade de se proceder a um registo 
de grande escala. 
Métodos: Procedeu-se a uma coorte prospectiva de base multicêntrica internacional com critérios de 
selecção previamente definidos. O indicador principal do prognóstico foi definido como a ocorrência 
de morte ou dependência aos 6 meses de seguimento, enquanto dois indicadores secundários foram 
escolhidos para distinguir se o poder preditor das variáveis se verificava essencialmente para o curto 
ou longo prazo. Esses indicadores foram: morte dentro do período de 30 dias após o início dos 
sintomas; e morte tardia ou dependência aos 6 meses. 
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Resultados: Vinte e dois doentes de 8 países foram incluídos. A mortalidade aos 6 meses foi de 
23.8%, enquanto a proporção de mortes ou dependência foi de 57.1%. Dos preditores gerais do 
prognóstico que foram também significativos para o curto termo, destaca-se a ocorrência de 
transformação hemorrágica antes da primeira intervenção neurocirúrgica (P=0.029), enquanto para 
os que tiveram efeito concomitante no longo termo se salienta: complicação pós-operatória com 
infecção extracraniana (P=0.016) e retalho ósseo de menor dimensão produzido aquando da 
craniectomia (P=0.044). 
Conclusões: A taxa de mortalidade associada à cirurgia descompressiva continua a suportar a 
indicação para execução deste procedimento. Consideramos que a melhoria prognóstica destes 
doentes passa por definir um limite mínimo para a extensão da craniectomia descompressiva, bem 





Cerebral venous and dural sinus thrombosis (CVST)  are rare forms of stroke, that usually appear to 
affect more frequently young adults and children [1]–[3]. Although most patients with CVST have 
favourable clinical outcomes, a proportion of these (13-25%) are at high risk for early death or 
dependency in the long-term [1], [4]. Acute deaths are mainly attributed to transtentorial herniation, 
as a consequence of large venous infarction and intraparenchymatous haemorrhage [5], [6]. Recent 
evidence has been published about the benefits of decompressive surgery in the outcome of these 
patients and, presently, it is considered a life-saving procedure associated with good functional 
outcome [7]. Nevertheless, scarce information has been published in the matter of outcome 
assessment of this group of patients, and most of it comes from uncontrolled retrospective studies. 
Our aim with this investigation is to produce an interim analysis of the ongoing registry for 
Decompressive Surgery in Cerebrovenous Thrombosis, in order to identify potential outcome 
predictors and verify if post-operative decompressive surgery outcomes justify the investment in 
proceeding with a large case series registry. 
Patients and Methods 
Study design 
This study is a multicentric international prospective cohort which includes patients from different 
medical centres around the world. In order to do this, a formal invitation was made to previous active 
investigators on the area of cerebral venous and sinus thrombosis and to any other medical doctor 
that may have been considered or manifested interest in CVST and neurointensivism. Patient 
inclusion in the study assumes an accomplishment of the eligibility criteria, which are subsequently 
described. The maximum follow-up period was 12 months, with periodic clinical assessments 
occurring preferably by direct interview in an outpatient clinic visit, at 6 and 12 months. 
Eligibility Criteria 
The investigators were asked to report all the cases of CVST who: were diagnosed by an imaging 
method such as Magnetic Resonance, Magnetic Resonance Venography, Computerized Tomography 
Venography or Intra-arterial Venography; who had a documented parenchymal lesion (ischaemic or 
haemorrhagic) or diffuse brain oedema by CT or MR; and who were treated by decompressive 
craniectomy or haematoma evacuation. They were excluded all the cases of CVST which diagnosis 
was only supported by angiography (or by any other means than the ones defined) and also the 
situations when there was an association with head trauma or other intracranial disease with a 
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potential indication for decompressive surgery. The study was approved by local ethics committees 
and patients or relatives gave informed consent. 
Variables 
We provide a brief description of the baseline characteristics of the selected sample, with regard to 
demographics, clinical manifestations, neuroimaging results, risk factors, clinical course, treatments 
and complications. Our results were measured according to a primary endpoint of the outcome, 
which was defined as death or dependency at 6 months (modified Ranking Scale score, mRS, equal 
or greater than 3). We chose the outcome assessment from 6
th
 month follow-up as primary endpoint 
because, as our investigation is still ongoing, this was the parameter were we had information from 
the largest number of patients, factor that in our perspective was critical to confer some reliability to 
the produced statistical inferences. Two other secondary endpoints were defined: early deaths (deaths 
within 30 days after symptom onset) and late deaths or dependencies at 6 months follow-up. The 
main objective of our analysis was to examine significant statistical relationships between relevant 
characteristics of our sample and our primary endpoint, in order to identify potential predictors for 
unfavourable outcome in CVST patients submitted to decompressive surgery. Bivariate cross-match 
with secondary endpoints was performed with the purpose of distinguishing short-term from long-
term unfavourable outcome predictors. We believe that doing this split we yield a better assessment 
of the clinical deterioration impact that each predictor variable produces on the outcome.  
Data measurement 
The timing, type and technical details of the neurosurgical intervention were left to the initiative and 
option of the local investigator and neurosurgeons. Outcome was measured at the day of hospital 
discharge, 6
th
 month and 12
th
 month follow-up assessments. It was used the modified Rankin Scale 
[8], which score was evaluated by an investigator not directly involved in the surgical intervention. 
Bias 
This study was conceived with the objective of validating previous conclusions about the impact of 
decompressive surgery on the outcome of complicated CVST. To date, most of the scientific 
evidence on the topic comes from retrospective and case-report studies. In order to control potential 
sources of bias, we designed a prospective registry so that every patient who accomplished eligibility 
criteria had the opportunity to be incorporated in the investigation, thereby minimizing the risk for 
selection bias. We also defined a form and a protocol for registering and communicating data to the 
coordinating centre. We believe to be reducing any sources of information bias with this procedure. 
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22 patients were included 
4 patients died during 1st admission  
18 patients were alive at discharge 
1 patient died before 1st follow-up assessment 
1 patient withdrew from the study 
16 patients were alive at the end of 1st 
follow-up (6 months) 
13 patients with 2nd follow-up completed 
(12 months) 
3 patients waiting to complete 2nd follow-up 
(12 months) 
DISCHARGE: 
n= 22  
1ST FOLLOW-UP 
ASSESSMENT: 










Descriptive statistics for baseline variables were calculated, using frequencies for categorical 
variables and means and standard deviation for continuous variables. Bivariate analysis of the 
outcome with predictor variables was performed for categorical data with Fisher exact test and 
Mann-Whitney U test for continuous variables. Every variable with a p-value <0.05 was considered 
statistically significant. Phi coefficient was used as a measure of the degree of association between 
categorical predictors and the outcome. Predictor variables with Phi coefficients between 0.3 and 0.7 
(or -0.3 and -0.7) were considered to have a positive (or negative) moderate association with the 
outcome. Values above 0.7 (or below-0.7) were considered to show a strong positive (or negative) 
association. An absent or negligible association was attributed to variables with Phi coefficients 
between -0.3 and 0.3.   All the cases with missing observations on the tested variables were excluded 




Participants in the study came from 11 different 
medical centres situated in 8 different countries. 
Presently, we count with a total of 22 patients 
already included. Patient inclusion in each stage 
of the investigation and mortality data are 
displayed in Figure 1.  
With regard to baseline characteristics, mean 
patient’s age was of 37.6 years and 19 from 22 
patients were female (86.4%) (see Table I). The 
diagnosis of CVST was established by CT 
venography in 15 patients (68.1%) and by 
MRI/MR venography in 6 (27.2%) and DWI/PWI 
in 1 (4.5%). Most frequent occluded 
sinuses/cerebral veins (Table I) were superior 
sagittal sinus (12 patients, 54.5%), left lateral sinus 
(11 patients, 50%) and cortical veins (9 patients, 
42.9%). We calculated a mean sinus score of 2.1 
(SD 1.13). Mode of symptoms onset (Table I) was 
predominantly acute (10 cases, 45.5%) and 
subacute (11 cases, 50%) rather than chronic (1 
case, 4.5%). 
  
Table I. Demographics, occluded sinuses/veins and 








   
Mean age (y) = 37,6 (range 22-51), std. deviation 9,53 
Median age (y) = 38       
Female 19   86.4 
Male 3   13.6 
Occluded sinus/vein 
   
Superior sagittal sinus 12   54.5 
Left lateral sinus 11   50 
Right lateral sinus 5   22.7 
Straight sinus 2   9.1 
Deep venous system 1   4.5 
Cortical veins 9 1 42.9 
Left jugular vein 7   31.8 
Right jugular vein 2   9.1 
Mean sinus score = 2,1 (range 1-6), std. deviation 
1,13 
Mode of onset 
   
Acute (<48h) 10   45.5 
Subacute (48 to 30 days) 11   50 
Chronic (>30 days) 1   4.5 







Symptoms and signs 
   
Headache 21 1 100 
Decreased visual acuity 5 1 23.8 
Papilledema 3 4 16.7 
Neck stiffness 2 1 9.5 
Diplopia 2 1 9.5 
Aphasia 14   63.6 
Ataxia 1 1 4.8 
Visual field defect 6 2 30 
Nausea 11 1 52.4 
Left paresis 7 1 33.3 
Right paresis 9 1 42.9 
Any paresis 14 1 66.7 
Focal seizure 8   36.4 
Generalized seizure 8   36.4 
Any seizure 10   45.5 
Mental status 
disturbance 
15   68.2 
Decreased alertness 18   81.8 
Glasgow coma score on 
admission    
15 5   22.7 
9 to 14 8   36.4 
<9 9   40.9 
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Median delay from onset of symptoms to 
diagnosis was of 2 days (mean=4.41; SD 5.32 
days) where most prominent symptoms (Table II) 
were headache (22 cases, 100%), decreased 
alertness (18, 81.8%), mental status disturbance 
(15, 68.2%), any paresis (14, 66%) aphasia (14 
patients, 63.6%) and nausea (11 patients, 52.4%). 
Nine patients (40.9%) were comatose (GCS<9) at 
admission (Table II).  
Eighteen patients (81.6%) were identified with 
cerebral oedema and 21 patients (95.5%) had a 
documented parenchymal lesion (Table III).   







Summary of imaging 
results    
Cerebral oedema 18   81.6 
Parenchymal lesion 21   95.5 
Non-haemorrhagic 
lesion 
6   27.3 
Haemorrhagic 
infarction  
17   77.3 
Intracerebral 
hematoma 
11   50 
Subdural hematoma 2   9.1 
Subarachnoid 
haemorrhage 
5   22.7 
Bilateral lesion 4 1 19 
Multiple lesion1 10 1 47.6 
Left hemisphere 16   72.7 
Right hemisphere 9   40.9 
Posterior fossa 2   9.1 
Midline shift 16   72.7 
Transtentorial 
herniation 




7   31.8 
Mean lesion size (cm) = 6.25, std. deviation 2.18 
1 Only a maximum of 2. 







Risk factors 21 
 
95.5 
Transient 20   90.9 
Pregnancy 2   9.1 
Puerperium 5   22.7 
Any infection 4   18.2 
Systemic infection 1   4.5 
SNC infection 2   9.1 
ENT infection 4   18.2 
Severe dehydration 2   9.1 
Oral contraceptives 8   36.4 
Other prothrombotic 
drugs 
2   9.1 
Permanent 10   45.5 
Genetic thrombophilia  3   13.6 
Malignancy 1   4.5 
Severe anaemia 3 1 14.3 
Inflammatory bowel 
disease 
2   9.1 







Type of worsening 
   
Decreased alertness 16 3 84.2 
Mental state disturbance 9 3 47.4 
Worsening of previous 
motor/focal defect 
9 3 47.4 
New motor/focal defect 2 3 10.5 
New seizure 1 3 5.3 
Decreased visual acuity 1 3 5.3 
Neuroimaging    
New non-haemorrhagic 
lesion 
3 3 15.8 
Haemorrhagic 
transformation 
5 3 26.3 
New intracerebral 
haemorrhage 
5 3 26.3 
Enlargement of previous 
haemorrhage 
6 3 31.6 
Increasing in brain oedema 16 3 84.2 
Midline shift 21 1 100 
Transtentorial herniation 15 1 71.4 
Compression of 
brainstem/IV ventricle 
15 1 71.4 
Mean diameter of largest lesion (cm) = 8.37 (range 6-
13), std. deviation 2.11 
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This lesion was associated with haemorrhagic infarction in 17 cases (77.3%) and intracerebral 
hematoma in 11 (50%). It was preferably located in left hemisphere in 16 (72.7%), [versus 9 patients 
(40.9%) in right hemisphere], and it was bilateral in 4 (19%). In 16 patients (72.7%), the lesion 
produced a significant mass effect leading to an identifiable midline shift of cerebral structures and 
also, simultaneously, in 7 cases (31.8%) to transtentorial herniation. See Table VI for further details 
on midline shift degree. The maximal diameter of largest lesion at admission had a mean of 6.25 cm 
with a standard deviation (SD)=2.18 cm. 
Considering risk factors (Table IV), 21 patients (95.5%) had at least one risk factor for CVST. We 
recognised transient risk factors in 20 patients (90.9%) and permanent ones in 10 patients (45.5%). 
The most common transient risk factors identified were oral contraceptives, puerperium and ear, 
nose or throat infection. Most common permanent risk factor was genetic thrombophilia. There was a 
median of 2 risk factors per patient (mean=2,05; SD=1,13). 
Changes to clinical course (Table V) were predominantly marked by decreased alertness (16 cases, 
84.2%), mental state disturbance (9 cases, 47.4%) and worsening of previous motor/focal defect (9, 
47.4%). Five additional patients became comatose before surgery (GCS<9) reaching a total of 16 
(76.2%).  
 
Before surgery, every patient had a recognisable midline shift (see Table VI for comparison with 
midline shift degree on admission), 16 patients (84.2%) increased in brain oedema and 15 (71.4%) 
suffered transtentorial herniation and compression of brainstem or fourth ventricle. With respect to 
clinical deterioration pathogenesis, there was an enlargement of previous haemorrhage in 6 cases 
(31.6%), new intracerebral haemorrhage in 5 (26.3%), haemorrhagic transformation (5, 26.3%) and 
new non-haemorrhagic lesion (3, 15.8%). The mean diameter of the largest lesion shifted to a mean 
of 8.37 cm, SD=2.11cm before surgery (Table V).  
Table VI. Comparison between midline shift degree 













< 5 mm 11 50 2 9.5 
5 to 10 mm 6 27.3 7 33.3 
> 10 mm 5 22.7 12 57.1 







Decompressive craniectomy 15   68.2 
Hematoma/brain tissue 
evacuation 
1   4.5 
Both procedures 6   27.3 
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The neurosurgery intervention (Table VII), at 
admission, was essentially marked by two 
different procedures: decompressive craniectomy 
(DC) and brain tissue/haematoma evacuation 
(BTHE). Fifteen patients (68.2%) did DC alone, 
and one (4.5%) did BTHE. Six patients (27.3%) 
were submitted to both. 
Most common complications after surgery (Table 
VIII) were the occurrence of an extracranial 
infection (9 patients, 40.9%) and seizures (3 
patients, 14.3%). Three patients (13.6%) had to 
be submitted to a second neurosurgery (Table 
VIII) before discharge, mainly for external 
ventricular drainage and new BTHE. Medical 
treatments (Table VIII) were, essentially, use of 
sedation and mechanical ventilation (19 patients, 
86.4%), anticoagulation with any form of heparin 
(19 patients, 86.4%), hospitalisation in an 
intensive care unit (17 patients, 77.3%) and use 
of anti-epileptic drugs (11 patients, 50%). Mean 
hospital stay at discharge was of 34.9 days 
(median 22.5) with an SD=32.5 days. 
As far as follow-up period is concerned, after 
patient discharge and before 6
th
 month clinical 
assessment, the most frequent events (Table IX) 
were seizures (3 patients, 20%), venous 
thrombotic events in another territory (2, 12.5%) 
and the occurrence of sinking skin flap (2, 
13.3%). 
  
Table VIII. Post-operative complications, new 







Complications after surgery 
   
Seizure 3 1 14.3 
Sinking flap 1   4.5 
Paradoxical herniation 1   4.5 
External brain tamponade 1   4.5 
Intracranial bleeding 
   
Intracerebral 2   9.1 
Epidural 1   4.5 
Infection    
Meningitis 1   4.5 
Operative wound 1   4.5 
Extracranial infection 9  40.9 
Sepsis 3   13.6 
Pulmonary 3   13.6 
Other 5   22.7 
Pulmonary embolism 1   4.5 
Cardiac 2   9.1 
Other (pericarditis and 
sinus tachycardia) 
4   18.2 
New neurosurgery 3   13.6 
Hematoma/brain tissue 
evacuation 
 2    9.1 
External ventricular 
drainage 
 2    9.1 
Cranioplasty  2    9.1 
Medical treatments    
IV heparin 11   50 
SC heparin/LMWH, 
prophylactic dosages 
14   63.6 
SC heparin/LMWH, 
therapeutic dosages 
17   77.3 
Any heparin 19   86.4 
Oral anticoagulants 7   33.3 
Antiplatelet drugs 1   4.5 
Mechanical thrombolysis 1   4.5 
Anti-epileptic drugs 11   50 
Diuretics 5   22.7 
Anti-osmotics 9   40.9 
Sedation and mechanical 
ventilation 
19   86.4 
ICU 17   77.3 
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Eight patients (50%) required a new neurosurgical 
intervention, from 11 (68.8%) which had been 
admitted to the hospital. After 6
th
 month follow-up 
and before last clinical assessment (which occurred 
at 12
th
 month) (please see Table X), seizures 
continued to be the most frequent complication (6 
patients, 46.2%). Four patients (30.8%) required a 
neurosurgical intervention during this period from 5 (41.7%) who had new hospital admissions. New 
surgical interventions during follow-up periods happened fundamentally to perform cranioplasty. 
Outcome data 
Most of deaths were verified during 
admission (4 patients, 18.2%). Additionally, 
death or dependency was also the highest on 
discharge, counting with 20 patients 
(90.9%). On the other hand, no complete 
recoveries were achieved on this stage. At 
first follow-up period (before 6 months 
assessment), one new death was recorded, 
increasing total mortality rate up to 23.8%. 
Conversely on first follow-up assessment (6 
months), death or dependency was reduced 
to 57.1% and two complete recovery cases 







Events since last observation 
Death 1 2 6.3 
Other venous thrombotic 
event 
2 2 12.5 
Visual loss 1 2 6.3 
Seizure 3 3 20.0 
Sinking skin flap 2 3 13.3 
Infection 
   
Intracerebral 1 2 6.3 
Pulmonary 1 2 6.3 
Other events 1 2 6.3 
Hospital admission 11 2 68.8 
New neurosurgery 8 2 50 
External ventricular 
drainage 
2 2 12.5 
Ventriculo-
peritoneal/atrial shunt 
1 2 6.3 
Lumbar-peritoneal 
shunt 
1 2 6.3 
Cranioplasty 7 2 43.8 







Events since last observation 
Seizure 6 3 46.2 
Intracranial bleeding       
Intracerebral 1 3 7.7 
Infection 
   
Other (non-CNS, 
pulmonary or sepsis) 
1 3 7.7 
Hospital admission 5 4 41.7 
New neurosurgery 4 3 30.8 
Cranioplasty 
4 3 30.8 






Outcome at 6 
months (n=21) 












0 0 0 2 9.5 1 6.3 
2 2 9.1 7 33.3 7 43.8 
3 3 13.6 4 19 5 27.8 
4 7 31.8 3 14.3 0 0 
5 6 27.3 0 0 0 0 
Death 4 18.2 5 23.8 5 27.8 
CR2 0 0 2 9.5 1 6.3 
DD3 20 90.9 12 57.1 10 55.6 




were identified (9.5%). At last follow-up period (before 12 months assessment), despite 3 patients 
are still completing this stage, no new deaths have been registered. On second follow-up assessment 
(12 months), death or dependency proportion continued to diminish within our sample (55.6%). For 
further details please see Table XI. 
 
Bivariate analysis 
Death or dependency at 6 months (our primary endpoint to assess unfavourable outcome) showed 
significant statistical association with the following categorical variables: new haemorrhagic 
transformation before first neurosurgical intervention (p value= 0.029, Phi coefficient= 0.555) and 
complication of the post-operative period with an extracranial infection (p value= 0.016, Phi 
coefficient= 0.556). In relation to the produced bone flap size during craniectomy, we found that 
smaller bone grafts were more frequently associated with unfavourable outcome patients’ subgroup. 
Mann-Whitney U test was used and it was achieved a level of significance of 0.044. Descriptive data 
from bone flap size for “death or dependency at 6 months” subgroup was the following: mean= 11.0 
cm, SD= 3.30 cm (versus a mean=13.0 cm, SD= 2.06 cm for the distribution of the patients with 
better outcome). 
In the matter of predictors of death within 30 days after symptoms onset (early deaths), a significant 
statistical relationship was displayed for new haemorrhagic transformation before first neurosurgical 
intervention (p value= 0.010, Phi coefficient=0.725), localization of the lesion in the posterior fossa 
(p value= 0.026, Phi coefficient= 0.671), and use of intravenous heparin as therapeutic approach (p 
value= 0.045, Phi coefficient= -0.471). In relation to the extent of the parenchymatous lesions 
assessed before surgery, it was also noted that early deaths’ subgroup tend to have larger lesion 
diameters than the rest of the sample. Mann-Whitney U test showed a level of significance of 0.040. 
Descriptive data on pre-surgery largest lesion size for the early deaths’ subgroup showed a mean of 
10.7 cm with a SD= 1.16 cm (versus a mean of 8.0 cm with a SD=2.00 cm for the other patients).  
Concerning late deaths or dependencies at 6 months (long-term unfavourable outcome), significant 
association was achieved with the manifestation in the post-operative period of an extracranial 
infection (p value= 0.003, Phi coefficient= 0.764). Smaller bone flap sizes (p value= 0.038) were 
also more frequent among this subgroup of patients, where bone grafts had a mean of 10.7 cm with a 





Primary outcome, which was death or dependency at 6 months, reached a frequency of 57.1% what 
is considerably above death or dependency frequencies previously reported at last follow-up 
assessments in previous studies (see Table XII). Mortality at 6 months was, however, within 
described percentages interval (Table XII). It attained a proportion of 23.8% of patients. 
Primary endpoint predictors for unfavourable outcome were new haemorrhagic transformation 
before first neurosurgical intervention, smaller bone flap sizes produced during craniectomy, and 
complication of the post-operative period with an extracranial infection. With regard to specific early 
death predictors, they were identified positive associations with localisation of parenchymatous 
lesions in the posterior cranial fossa, larger lesions assessed immediately before surgery and new 
haemorrhagic transformation before first neurosurgical procedure. A negative association was found 
with the use of intravenous heparin as medical treatment. Specific late death and dependency 
predictors at 6 months were smaller bone flap sizes produced during craniectomy and extracranial 
infection as a complication of the post-operative period. 
Strengths of the study are the clear definition of inclusion and exclusion criteria and the prospective 
registry of data, which eliminates the risk for selection and recall bias. Furthermore, as we are 
investigating a group of patients with very rare characteristics, the inclusion of individuals from 
diverse countries in the world increases the external validity of conclusions verified in the study by 
reducing the importance of local environmental confounding factors. It is also the first prospective 
registry with multicentric investigational contribution that has been done on the topic. Limitations of 
the study were the short number of patients that was achieved for this interim analysis, which 
restricts the power of statistical analysis of predictors’ relationship with the outcome. The 
observational character of the study may also be a limitation when considering the elimination of any 
sources of bias, by opposition to randomized controlled trials. However, control with placebo is 
unsuitable for this type of life-saving intervention as it may be considered unethical. 
Twelve previous case series of patients with CVST submitted to decompressive surgery have been 
published (see Table XII). It is reported only one small prospective study, with patients from one 
single centre [9], while the other investigations are mainly retrospective in nature, or correspond to 
multiple case-reports. Considering series with a minimum of 5 patients submitted to surgery (which 
have happened since 2010), we observe that mortality in this group of patients ranges from 12.5-
29%. Favourable outcome (with mean/median last follow-up assessments taking place between 7 and 




























Raza E[1] 2014 12 years Retrospective Pakistan 7 
18 months 
(median) 
29% 43% 57% ? 
Aaron S[2] 2013 10 years Retrospective India 44 1 year /6 months 20%/20% 39%/44% 61%/56% 48%/38% 
Vivakaran T[3] 2012 2 years Retrospective India 34 
12 months 
(mean) 
17.7% 24% 76% ? 
Zuurbier S[9] 2012 4 years Prospective Netherlands 10 12 months 20% 30% 70% 50% 







15.9% 43.5% 56.5% 37.7% 
Mohindra 
S[10] 
2011 6 years Retrospective India 13 
35 months 
(median) 
15% 31% 69% ? 
Théaudin 
M[11] 
2010 7 years Retrospective France 8 
23 months 
(median) 
12.5% 25% 75% 75% 
Lath R[12] 2010 6 years Retrospective India 11 
7 months  
(mean) 
27% 27% 73% ? 
Lanterna L[13] 2009 3 years Retrospective Italy 3 1-6 months 0% 33% 67% ? 
Coutinho J[14] 2009 2 years 
Case-report 
series 
Netherlands 3 NA 33% 33% 67% ? 
Keller E[15] 2005 4 years 
Case-report 
series 
Switzerland 4 NA 0% 0% 100% ? 
Stefini R[16] 1999 ? 
Case-report 
series 
Italy 3 NA 0% 33% 67% 67% 






This classification was mainly attributed to patients having a maximum score of 2 in mRS scale or a 
minimum score of 4 in Glasgow outcome scale. Many studies do not report complete recovery rates, 
nevertheless, an interval between 37.7% and 75% is described. In our series, as previously 
mentioned, mortality is in accordance to the percentages defined in the literature, although we 
verified higher dependency rates and less complete recoveries. There are some reasons that can be 
pointed out to explain this discrepancy of data: First of all, our outcome reference comes from a 
follow-up which happened 6 months after discharge, while published references had mostly a 
minimum of 12 months follow-up. Aaron et al. mentions that mRS scale continues to improve even 
after 6 months [2]. Secondly, we are conducting a multicentric prospective cohort which may 
eliminate some potential sources of bias. We can observe that discrepancies were predominantly 
noted in dependencies classification, (which result from the subjective assessment of the 
investigator), rather than mortality that is a quite objective criterion. In this regard, we understand 
that morbidity in this high risk group of patients may be higher than what was previously considered. 
These results continue to support the execution of decompressive surgery in this high risk group of 
patients, as mortality without this procedure would be close to 100% [11], though we recognise the 
limitations of our statistical inference, particularly because of a small patient sample. We expect to 
answer more clearly to this question when our study is complete with a sample close to 100 patients. 
According to what is said in the literature about the outcome predictors in cerebral venous 
thrombosis patients, haemorrhagic infarction, transformation of previous ischemic lesions and 
expanding haemorrhagic infarcts are considered a major risk factor for poor outcome [1], [4], [9], 
[17], [18]. In our study, the haemorrhagic transformation (HT) of a previous ischemic infarct lesion, 
before first neurosurgical intervention, was one of the most important predictors identified for 
unfavourable outcome. It demonstrated a moderate positive association with death or dependency at 
6 months and a strong positive association with death within first 30 days after clinical onset. In this 
way, we interpret HT as an early mortality predictor, which aetiology requires clarification. To date, 
the only published scientific evidence we have on this process comes from major clinical trials of 
acute ischemic stroke interventions, which demonstrated increasing haemorrhagic rates with 
endovascular interventions, as well as with increased time lapses between stroke onset and vessel 
recanalization [19]–[21]. Despite the need for new efforts on clarifying HT causes and precipitants in 
the context of cerebral venous thrombosis, we perspective, as it was earlier recognised by Mohindra 
et al., that there may be a role in defining an optimal time for surgical intervention [10], in order to 
minimize this type of event. Further investigation on endovascular treatment approaches as a 




“decompressive craniectomy may be beneficial in patients who develop haematoma following 
thrombolysis therapy” [12]. 
With regard to bone flap size produced at decompressive craniectomy, it is already reported a 
concern, in previous investigations of CVST patients, about producing wide and extensive 
craniectomies with the objective of preventing damage to the swollen brain by the edges of the bony 
opening [10] and to avoid or reverse transtentorial herniation [9]. In our series, smaller bone flap 
sizes were associated with poorer outcome rankings at six months, either in the view of general 
outcome predictors as well as long-term outcome predictors. Patients with unfavorable outcome had 
a mean of 11 centimeters bone flap sizes, while favorable outcome group achieved a mean of 13 
centimeters. There is recent evidence in the matter of decompressive hemicraniectomies (DHC) that 
if a minimum threshold of 12 centimeters for DHC size and decompression to the temporal base are 
observed, a smaller craniectomy is equally effective in relieving intracranial hypertension and does 
not increase the risk for early secondary complications such as parenchymal shear stress, hemorrhage 
and swelling [22]. It still needs to be studied if this reported lower threshold size for DHC assures the 
same favourable outcome in long-term and if it is applicable to other craniectomy types (other than 
DHC). No surgical risk and complications data have yet been clearly defined for very extensive 
craniectomies, although some authors suggest it may predispose to the occurrence of sinking skin 
flap syndrome [23]. Considering the exposed evidence, we are in favour of the execution of larger 
craniectomy bone flaps with a minimum of 13 cm, as it corresponds to the average bone flap size of 
favourable prognosis patient group. 
Extracranial infection during first hospitalisation appears to be a frequent post-operative 
complication. Raza et al. reports that in their patient series investigation, “every hospital stay was 
complicated with a hospital acquired non-central nervous system infection” [1]. Most frequent types 
of infection reported within this category are urinary, pulmonary tract infections and sepsis [1]–[3]. 
Within our patients, 41% had an extracranial infection, which was correlated with an unfavourable 
outcome at 6 months, especially through the expression of an increased rate of dependencies at 6
th
 
month follow-up. In this fashion it is suggested that extracranial infection may be a long-term 
predictor of unfavourable outcome. Nevertheless, we believe that this variable may result from an 
important neurologic deficit that impairs mobility, as well as other important physiologic functions, 
predisposing in this matter to infection. Considering this true, this variable would not actually be an 
independent predictor of the outcome but instead a result variable of a severe dependence already 
present on admission. We therefore recognise extracranial infection as a possible marker for 




type of infection with antibiotics would be beneficial for overall patient outcome. Same observations 
have been made in analogous studies for acute stroke [24], [25]. 
Posterior cranial fossa lesions and larger lesions assessed immediately before surgery were 
apparently associated with the occurrence of deaths during first admission. Treatment with 
intravenous heparin suggests reducing the frequency of these early deaths. In this regard, Canhão et 
al. already described posterior cranial fossa lesions as an independent predictor of death in CVST 
patients [26]. Many authors have considered the occurrence of large venous infarcts as high mortality 
risk factor, and which constitutes one of the prime indications for decompressive surgery [2], [6], 
[12], [27]. No considerations have conversely been made about parenchymal lesion size within this 
high group of patients. With regard to heparin use in CVST, its indication as primary therapy has 
long been considered although such recommendations are based on limited evidence from clinical 
trials [7], [28], [29]. A beneficial effect in early deaths is here suggested with the use of intravenous 
heparin. We should, however, take into account that the former three variables did not show a 
significant correlation with primary endpoint, which was death or dependency at 6 months. We 
therefore consider that, despite an identifiable correlation with secondary endpoints from the study, 
association with primary endpoint needs to be retested in a larger case series, in order to accurately 
define the real contribution, (and consequently the clinical relevance) of these predictor variables on 
patients outcome. 
In conclusion, previous mortality rates in the order of 20-30% were confirmed in our investigation 
for CVST patients submitted to decompressive surgery. This supports the execution of 
decompressive surgery in this high risk group of patients, as mortality without this procedure would 
be almost certain. Our results, however, suggest a higher dependencies proportion and smaller 
complete recovery frequencies, which require confirmation through large scale prospective case 
studies. Haemorrhagic transformation before neurosurgery intervention was found to be an important 
marker of unfavourable outcome and early mortality.  Strategies to minimize this type of event 
require further investigation. Defining an optimal time for surgical intervention and the assessment 
of endovascular treatment use may have a role in this process. Smaller bone flap sizes at craniectomy 
procedure appear to predict for poor outcome and lower recovery rates in the long-term. A mean of 
13 cm of bone flap size was found in favourable outcome patients’ subgroup. Long-term beneficial 
effects of larger craniectomies need to be tested in further studies.  Extracranial infection was 
associated with overall and long-term unfavourable outcomes, although its contribution as an 
independent risk factor is unlikely. Any attempt of its prophylactic prevention with antibiotics is 




and contributors of the outcome, matter that we expect to clarify when our study is complete, with a 
sufficiently large patient sample. 
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